IRLA — IRulya Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1662774 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 584,000 | 0 | -79,782,000 | -75,488,000 | 123,995,000 | 115,981,000 | 15,508,000 |
| Mar 2026 | 160,000 | 0 | -14,590,000 | 35,912,000 | 26,623,000 | 18,163,000 | 10,951,000 |
| Sep 2025 | 300,000 | 0 | -13,430,000 | -13,442,000 | 109,899,000 | 6,452,000 | 108,840,000 |
| Jun 2025 | 311,000 | 0 | -10,427,000 | -16,049,000 | 117,210,000 | 16,826,000 | 105,474,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-46,923,000
Investing CF
$26,291,000
Financing CF
$121,786,000
CapEx
$-352,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-73.46
As of
2026-10-17
Annual Trend (SEC EDGAR, last 7y)
Revenues vs Net Income (last 7y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,244,000 | -58,068,000 | -83,979,000 | 93,523,000 | 129,237,000 | -35,714,000 | — |
| Dec 2024 | 2,929,000 | -57,285,000 | -56,828,000 | 114,478,000 | 84,332,000 | 30,146,000 | — |
| Dec 2023 | 3,478,000 | -34,620,000 | -31,385,000 | 167,900,000 | 82,816,000 | 85,084,000 | — |
| Dec 2022 | 1,068,000 | -52,015,000 | -51,660,000 | 103,910,000 | 3,317,000 | 100,593,000 | — |
| Dec 2021 | 620,000 | -90,318,000 | -89,945,000 | 133,228,000 | 14,642,000 | 118,586,000 | — |
| Dec 2020 | 2,044,000 | -78,893,000 | -76,849,000 | 189,466,000 | 17,204,000 | 172,262,000 | — |
| Dec 2019 | 0 | -39,168,000 | -36,980,000 | 124,370,000 | 8,892,000 | 115,478,000 | — |
TTM Snapshot
Revenues TTM
$1,271,000
NetIncome TTM
$-92,476,000
OpCashFlow TTM
—
Assets (Latest)
$123,995,000
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AMGN | AMGEN INC | $233.82B | $432.49 | — |
| GILD | GILEAD SCIENCES, INC. | $193.67B | $156.19 | — |
| MRNA | Moderna, Inc. | $87.04B | $218.01 | — |
| ARGX | ARGENX SE | $50.94B | $819.14 | — |
| RVMD | Revolution Medicines, Inc. | $38.14B | $177.96 | — |
News headlines (Yahoo Finance, 1h cache)
Recent Insider Activity
No insider activity indexed for this ticker.